Nevirapine-based therapy after suppression: Can we switch?

Sharon Nachman; James McIntyre

doi:10.1016/S1473-3099(12)70061-0

Nevirapine-based therapy after suppression: Can we switch?

Sharon Nachman
, James McIntyre

Pediatrics

Stony Brook University

University of Cape Town

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	498-499
Number of pages	2
Journal	The Lancet Infectious Diseases
Volume	12
Issue number	7
DOIs	https://doi.org/10.1016/S1473-3099(12)70061-0
State	Published - Jul 2012

Access to Document

10.1016/S1473-3099(12)70061-0

Cite this

@article{2fd75051d0c44a198a5e38a89acf1495,

title = "Nevirapine-based therapy after suppression: Can we switch?",

author = "Sharon Nachman and James McIntyre",

year = "2012",

month = jul,

doi = "10.1016/S1473-3099(12)70061-0",

language = "English",

volume = "12",

pages = "498--499",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd.",

number = "7",

}

TY - JOUR

T1 - Nevirapine-based therapy after suppression

T2 - Can we switch?

AU - Nachman, Sharon

AU - McIntyre, James

PY - 2012/7

Y1 - 2012/7

UR - https://www.scopus.com/pages/publications/84862764648

U2 - 10.1016/S1473-3099(12)70061-0

DO - 10.1016/S1473-3099(12)70061-0

M3 - Letter

C2 - 22424721

SN - 1473-3099

VL - 12

SP - 498

EP - 499

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 7

ER -

Nevirapine-based therapy after suppression: Can we switch?

Access to Document

Other files and links

Fingerprint

Cite this